ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002

In Brief: Thomas Davis, Stanford Oncologist, Dead At 49; DeVita To Visit, NCI; Hunter Named WHI Liaison

September 4, 1992

NCI “Leadership Vacuum” Deepened?

December 22, 1994

Rauscher, ACS Oppose Kennedy Bill, Defend NCI Special Authority, Say Funding Level Inadequate

May 11, 1979

PROPOC Study Analyses Six Cancer DRGs

January 17, 1986

NCI Director Defends Goal to Eliminate Suffering, Death From Cancer by 2015

June 13, 2003